Skip to main content

Table 2 Effect of hormonal status on the TAM pharmacokinetics and its metabolites END, 4-HTAM and NDTAM in the investigated TAM-treated breast cancer patients (n = 40). Data are reported as the geometric mean (95% CI)

From: Hormonal status affects plasma exposure of tamoxifen and its main metabolites in tamoxifen-treated breast cancer patients

 Premenopausal (n = 20)Postmenopausal (n = 20) 
AUCτ (ng*h/mL)Geometric Mean95% CIGeometric Mean95% CIP-value
TAM2806.782128.193701.754829.414244.205495.30<  0.001
NDTAM11,643.868132.8816,670.5520,253.0917,886.4322,932.88<  0.010
4-HTAM61.6744.1586.15112.2398.75127.55<  0.001
END192.14111.75330.35452.77355.65576.400.013
Css (ng/mL)
 TAM116.9588.67154.24201.23176.84228.97<  0.001
 NDTAM485.16338.87694.61843.88745.27955.54<  0.010
 4-HTAM2.571.843.594.684.115.31<  0.001
 END8.014.6613.7618.8714.8224.020.013
Metabolic Ratios
 TAM/NDTAM0.200.150.260.210.190.230.523
 TAM/4-HTAM46.2736.6758.3938.1231.7945.700.177
 NDTAM/END68.9846.26102.8644.3532.7860.010.230
 4-HTAM/END0.300.200.440.240.190.310.275
Apparent clearance (L/h)
 TAM7.135.409.404.143.644.710.015
  1. Tamoxifen (TAM), endoxifen (END), 4-hydroxytamoxifen (4-HTAM) and N-desmethyl tamoxifen (NDTAM)